- Home
- MLGO vs MTVA Comparison
MLGO vs MTVA Comparison
Compare MLGO & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLGO
- MTVA
- Stock Information
- Founded
- MLGO 2018
- MTVA 2014
- Country
- MLGO China
- MTVA United States
- Employees
- MLGO N/A
- MTVA N/A
- Industry
- MLGO EDP Services
- MTVA
- Sector
- MLGO Technology
- MTVA
- Exchange
- MLGO Nasdaq
- MTVA NYSE
- Market Cap
- MLGO 15.6M
- MTVA 14.3M
- IPO Year
- MLGO N/A
- MTVA N/A
- Fundamental
- Price
- MLGO $0.61
- MTVA $0.62
- Analyst Decision
- MLGO
- MTVA Strong Buy
- Analyst Count
- MLGO 0
- MTVA 2
- Target Price
- MLGO N/A
- MTVA $7.50
- AVG Volume (30 Days)
- MLGO 39.9M
- MTVA 121.8K
- Earning Date
- MLGO 04-28-2025
- MTVA 08-13-2025
- Dividend Yield
- MLGO N/A
- MTVA N/A
- EPS Growth
- MLGO N/A
- MTVA N/A
- EPS
- MLGO 0.55
- MTVA N/A
- Revenue
- MLGO $74,185,505.00
- MTVA N/A
- Revenue This Year
- MLGO N/A
- MTVA N/A
- Revenue Next Year
- MLGO N/A
- MTVA N/A
- P/E Ratio
- MLGO $1.25
- MTVA N/A
- Revenue Growth
- MLGO N/A
- MTVA N/A
- 52 Week Low
- MLGO $0.50
- MTVA $0.61
- 52 Week High
- MLGO $185.20
- MTVA $5.16
- Technical
- Relative Strength Index (RSI)
- MLGO 33.92
- MTVA N/A
- Support Level
- MLGO $0.50
- MTVA N/A
- Resistance Level
- MLGO $0.75
- MTVA N/A
- Average True Range (ATR)
- MLGO 0.11
- MTVA 0.00
- MACD
- MLGO 0.15
- MTVA 0.00
- Stochastic Oscillator
- MLGO 36.39
- MTVA 0.00
About MLGO MicroAlgo Inc.
MicroAlgo Inc is divided into two segments: Central processing algorithm services & Intelligent chips and services. The majority is from the Central Processing Algorithm Services. which refers to a range of computing algorithms, analytical algorithms, recommendation algorithms, & acceleration algorithms. The businesses engaged in internet advertisement, game development, intelligent chip design, finance, retail, & logistics depend on the ability to process & analyze data with optimized computing software & hardware capable of handling the data workload. Intelligent chips and services revenues include revenues generated from the resale of intelligent chips. All of the Company's net revenues were generated in the PRC, Hong Kong, & Singapore, out of which the majority is from the PRC.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.